Sovihep V is a fixed-dose combination tablet containing sofosbuvir and velpatasvir, two direct-acting antiviral agents used in the treatment of chronic hepatitis C virus (HCV) infection. This once-daily oral therapy offers a simplified, pan-genotypic treatment regimen, effective across all major strains of HCV. It is designed to help eliminate the virus from the body, reduce liver damage, and prevent complications such as cirrhosis and liver cancer.

Mechanism of Action
Sovihep V works through the combined antiviral actions of its two components:

• Sofosbuvir is a nucleotide analogue that inhibits the HCV NS5B polymerase, an enzyme crucial for viral RNA replication. It becomes activated in the body and gets incorporated into viral RNA, causing premature termination of the replication process.

• Velpatasvir inhibits the NS5A protein, another viral component essential for both RNA replication and the assembly of new viral particles. By blocking NS5A, it disrupts the life cycle of the virus at multiple stages.

  Uses
  Sovihep V is indicated for the treatment of chronic hepatitis C infection in adults, regardless of genotype. It is effective in patients with or without liver cirrhosis and may be used in combination with other medications in certain complicated cases. Treatment typically lasts twelve weeks, depending on the patient’s clinical history and liver status.

  The goal of therapy is to achieve a sustained virologic response, meaning the virus becomes undetectable in the blood twelve weeks after completing treatment, which is considered equivalent to a cure.

  Adverse Effects
  Sovihep V is generally well tolerated by most patients.
  Common side effects include headache, fatigue, nausea, and insomnia. These are usually mild and temporary.
  Some patients may experience irritability, weakness, or digestive issues. When combined with other antiviral drugs, particularly ribavirin, the risk of side effects may increase, including anemia and skin reactions.